If you have been reading about alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-16. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
=== Agrochemical research === Hydrophobic insecticides and herbicides tend to be more active. Hydrophobic agrochemicals in general have longer half-lives and therefore display increased risk of adverse environmental impact.
==== Alzheimer's disease ==== Active AEP was found at increased levels and translocated to the cytoplasm of neuronal cells of AD patients. In AD the plaques are composed of amyloid beta, intracellular neurofibrillary tangles and tau protein. The dysfunction of APP proteolysis and the abnormal phosphorylation of tau lead to the formation of neuritic plaques and neurofibrillary tangles (NFTs), respectively, causing neuronal degeneration and dementia It also play a crucial role in behavior disorders connected with AD such as anxiety and depression. It also plays a role in stroke. Since stroke elicits acidity in the brain AEP become active due to low pH level. Then it cleaves SET which causes death of brain cells. Targeting of AEP might help to prevent onset of AD symptoms. Development of AEP-selective inhibitors (such as Cbz-L-Ala-L-Ala-AzaAsnchloromethylketone and aza-peptidyl AEP inhibitors) is crucial for helping with diseases.
Analytical chemistry has applications across science and industry. It is fundamental to forensic science (e.g., DNA fingerprinting and toxicology), bioanalysis (e.g., measuring drug concentrations in pharmacokinetic studies), clinical analysis (e.g., blood glucose monitoring and COVID-19 PCR testing), environmental monitoring (e.g., testing for pollutants in water and air), and materials science (e.g., quality control of semiconductors and nanomaterials). Great effort is being put into shrinking the analysis techniques to chip size. Although few examples of such systems compete with traditional analysis techniques, potential advantages include size/portability, speed, and cost. Micro total analysis system (μTAS) or lab-on-a-chip. Microscale chemistry reduces the amount of chemicals used. Many developments improve the analysis of biological systems. Examples of rapidly expanding fields in this area are genomics, DNA sequencing and related research in genetic fingerprinting and DNA microarray; proteomics, the analysis of protein concentrations and modifications, especially in response to various stressors, at various developmental stages, or in various parts of the body; metabolomics, which deals with metabolites; transcriptomics, including mRNA and associated fields; lipidomics, dealing with lipids and its related fields; peptidomics, dealing with peptides and its related fields; and metallomics, dealing with metal concentrations and especially with their binding to proteins and other molecules.
== External links == Cooking For Engineers: Smoke Point of Various Fats - another list of smoke points along with some discussion on the subject Good Eats: Cooking Oil Smoke Points Archived 2016-03-03 at the Wayback Machine The Culinary Institute of America (1996). The New Professional Chef (6th ed.). John Wiley & Sons.
== History == Prior to the 20th century, governments rarely made a major effort to proscribe recreational drug use, though several smoking bans were passed by authorities in Europe and Asia during the early modern era. Tobacco and opium were the two first drugs to be subject to prohibitory government legislation, with officials in New Spain, the Ottoman Empire, Germany, Austria and the Russian Empire passing laws against smoking tobacco; the government of the Qing dynasty issued edicts banning opium smoking in 1730, 1796 and 1800. Beginning in the 18th century, the East India Company (EIC) began to smuggle Indian opium to Chinese merchants, resulting in the creation of an illegal drug trade in China. By 1838, there were between four and 12 million opium addicts in China, and Qing officials responded by strengthening their suppression of the illegal opium trade. Incidents such as the destruction of opium at Humen led to the outbreak of the First Opium War between China and Britain in 1839; the 1842 Treaty of Nanking ending the war did not legalize the importation of opium into China, but Western merchants continued to smuggle the drug to Chinese merchants in ever-increasing amounts. The 1858 Treaty of Tianjin, which ended the Second Opium War, stipulated that the Qing government would open several ports to foreign trade, including opium. Western governments began prohibiting addictive drugs during the late 19th and early 20th centuries.
Sources: en.wikipedia.org
==== Sheath-flow interface ==== With the sheath-flow interface, the electrical connection between an electrode and background electrolyte is established when the CE separation liquid is mixed with sheath liquid flowing coaxially in a metal capillary tubing. In most popular commercial CE-ESI-MS interfaces an additional outer tube (three-tube coaxial design) with sheath gas is used, which help to improve electrospray stability and solvent evaporation. But it has been found that flow of sheath gas can cause suction effect near the capillary terminus, which lead to parabolic flow profile and, as a consequence, low separation efficiency. Commonly used sheath liquid is 1:1 mixture of water-methanol (or isopropanol) with 0.1% acetic acid or formic acid. The system is more reliable and has wide selection range of separation electrolyte. However, since flow rates of sheath liquid required for a stable electrospray are usually quite high (1-10 μL/min), here might be some decrease in sensitivity due to dilution of samples with sheath liquid. Sheath liquid can be delivered hydrodynamically (with a syringe pump) or electrokinetically. Electrokinetic method allows one easily operate in nanoelectrospray regime (ESI flow rates at nl/min) and thus to improve sensitivity.There are some new approaches and improvements for sheath-flow interface. To reduce the dead volume and to increase sensitivity extendable sheath-flow CE-ESI-MS interface was created. The outlet end of the separation capillary was treated with hydrofluoric acid to decrease thin of the wall and to taper the tip.
To increase the level of recycling and meet its targets, Tetra Pak engaged in driving recycling activities such as developing collection schemes, launching new recycling technologies, and raising awareness of recycling and sustainability. Used Tetra Pak packages have been recycled as construction material in design projects, with varying results. By 2017, 25% of Tetra Pak cartons were recycled globally. At that time, the company announced that global recycling rates would no longer be one of its main metrics measured in sustainability reports, abandoning its previous target of increasing recycling rates to 40% by 2020, and instead introduced new metrics to measure against, such as public outreach, access to recycling facilities, and recycling capacity. In 2018, Tetra Pak signed an agreement with the environmental services company Veolia "to recycle all the components of used beverage cartons collected within the EU by 2025." Tetra Pak has also partnered with the Certified Renovated Equipment organization to refurbish old equipment so it can be resold as part of a circular economy initiative. In attempts to innovate and to improve the recyclability rate of their Aseptic cartons, one of the main factors is the replacement of the aluminum layer used, which can constitute up to 5% of the package material. In which, exposure to the metal has been suggested as a risk factor for Alzheimer's Disease. The company is currently testing two alternatives as a replacement for aluminum: (1) a fiber-based barrier layer, and (2) a polymer-based barrier.
=== Dried fish and seafood === Drying fish is a method of food preservation that works by removing water from the fish, which inhibits the growth of microorganisms. Open-air drying using sun and wind has been practiced since ancient times to preserve food. Fish are also preserved through such traditional methods as smoking and salting.
==== Border walls ==== Border walls are a common aspect of border security measures worldwide. Border walls generally seek to limit unauthorised travel across an international border and are frequently implemented as a populist response to refugees and economic migrants. The India-Bangladesh barrier is a 3,406 kilometres (2,116 miles) long fence of barbed wire and concrete just under 3 metres (9 feet 10 inches) high, currently under construction. Its stated aim is to limit unauthorised migration. The project has run into several delays; there is no clear completion date for the project yet. Similar to India's barrier with Bangladesh and the proposed wall between America and Mexico, Iran has constructed a wall on its frontier with Pakistan. The wall aims to reduce unauthorised border crossings and stem the flow of drugs, and is also a response to terrorist attacks, notably the one in the Iranian border town of Zahedan on 17 February 2007, which killed thirteen people, including nine Iranian Revolutionary Guard officials. President Donald Trump's proposal to build a new wall along the border formed a major feature of his 2016 presidential campaign and over the course of his presidency, his administration spent approximately US$15 billion on the project, with US$5 billion appropriated from US Customs and Border Protection, US$6.3 billion appropriated from anti-narcotics initiative funded by congress and US$3.6 billion appropriated from the American military.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.